NAD+ (Nicotinamide Adenine Dinucleotide)

Clinical Summary

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every living cell, serving as an electron carrier in >500 enzymatic reactions and a substrate for sirtuins (SIRT1-7), PARPs (DNA repair enzymes), and CD38 (immune signaling). NAD+ levels decline 40–50% by age 70 across all measured tissues, driven by decreased NAMPT salvage pathway activity, increased CD38 consumption, and chronic PARP activation from accumulated DNA damage.

Direct oral NAD+ supplementation does not work — the molecule is too large and charged for GI absorption (<2% bioavailability). All effective NAD+ augmentation uses precursor compounds: Nicotinamide-Riboside (NR), NMN, nicotinamide (NAM), or niacin, which are absorbed and converted intracellularly.

Who benefits most: Adults >40 with metabolic risk factors, pre-hypertension, early neurodegenerative disease, or mitochondrial dysfunction. Evidence is strongest for NR (most human RCTs, GRAS status) and NMN (rapidly growing trial base, 2025 FDA legal clarification). Healthy young adults (<35) show less measurable benefit — their NAD+ levels are still relatively high.

Key 2024–2026 developments: NOPARK Phase 3 trial for Parkinson's completed (N=410); multiple meta-analyses confirmed metabolic benefits; head-to-head NR vs NMN comparison published (Nat Metab 2026); NR showed benefit in PAD (Phase 3), COPD (Nat Aging), and Werner syndrome (Japan RCT); NMN blood pressure meta-analysis published; FDA reversed NMN ban, declaring it a legal supplement.

Bottom line: NAD+ precursors (especially NR and NMN) have moderate-strong evidence for metabolic health, blood pressure, mitochondrial function, and Parkinson's disease. Evidence is growing for cognition, muscle function, and several other indications. Safety profile is excellent — FAERS data shows essentially no signal for either NR or NMN. The NR vs NMN choice is largely commercial rather than scientific; a 2026 head-to-head trial showed both approximately doubled circulating NAD+ with no significant difference.

Indications & Evidence

Reading this table: Stars = evidence volume and quality. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot data or strong animal + mechanistic | 2/5 Animal data only or very limited human | 1/5 No evidence, theoretical, or debunked

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

Metabolic Health / Insulin Sensitivity Protocol

Evidence: 4/5 | Key PMIDs: 33888596, 32060194, 30019234

Phase 1: Initiation (Weeks 1–2)

• NR 500 mg/d or NMN 250 mg/d, morning with or without food
• Baseline labs: fasting glucose, HbA1c, HOMA-IR, lipid panel, liver enzymes
• If on diabetes meds: increase glucose monitoring frequency

Phase 2: Therapeutic (Weeks 3–12)

• Escalate to NR 1000 mg 2×/d or NMN 500–1000 mg/d
• Fasting glucose check at week 4 and 8; HbA1c at week 12
• May need diabetes medication dose reduction if glucose dropping

Phase 3: Maintenance (Week 12+)

• Continue therapeutic dose; HbA1c every 3 months
• Expected: 10–15% insulin sensitivity improvement, 0.3–0.5% HbA1c reduction, liver fat reduction

Drug Interaction Timing: Space 2+ hours from metformin (theoretical enhanced effect). Monitor glucose closely with sulfonylureas/insulin — hypoglycemia risk. Stop/Reassess: If no metabolic improvement at 12 weeks despite adequate dosing and compliance.

Parkinson's Disease Protocol

Evidence: 4/5 | Key PMID: 35235774 (NADPARK)

Phase 1: Initiation (Week 1)

• NR 500 mg/d, morning, as adjunct to standard PD therapy
• Baseline: UPDRS score, neurological assessment

Phase 2: Therapeutic (Weeks 2–12)

• Escalate to NR 1000 mg/d
• Neurological assessment at 4 weeks
• Monitor for changes in dopaminergic medication needs

Phase 3: Maintenance (Month 3+)

• NR 1000 mg/d long-term (>6 months for progression outcomes)
• UPDRS scoring every 3–6 months
• NOPARK Phase 3 (NCT03568968, N=410) results pending — may update protocol

Expected Outcomes: Increased brain NAD+ and dopamine metabolites; potential slowed disease progression. This is the first human evidence of NAD+ precursor modifying neurodegenerative disease trajectory. Stop/Reassess: Only if adverse effects; otherwise continue indefinitely as adjunct.

Cardiovascular / Blood Pressure Protocol

Evidence: 4/5 | Key PMIDs: 29599478, 30766476

Phase 1: Initiation (Weeks 1–2)

• NR 500 mg/d, morning
• Baseline: BP (seated, 3 readings), arterial stiffness (PWV if available), lipid panel

Phase 2: Therapeutic (Weeks 3–8)

• NR 1000 mg/d (single or split dose)
• Weekly BP monitoring; expected 8–10 mmHg SBP reduction by week 6
• If on antihypertensives: watch for hypotension, may need dose reduction

Phase 3: Maintenance (Week 8+)

• Continue NR 1000 mg/d; BP every 1–3 months
• Expected: sustained BP reduction, 15–20% arterial stiffness improvement

Stop/Reassess: BP <90/60 with symptoms → reduce antihypertensives first, then consider NR dose reduction.

Cognitive Function / MCI Protocol

Evidence: 3/5 | Key PMIDs: 36515353, 37994989

Phase 1: Initiation (Weeks 1–2)

• NR 500 mg/d or NMN 500 mg/d, morning
• Baseline: MoCA or MMSE cognitive screening

Phase 2: Therapeutic (Weeks 3–12)

• NR 1000 mg/d (may split 500 mg 2×/d)
• Cognitive reassessment at week 12

Phase 3: Maintenance (Week 12+)

• Continue NR 1000 mg/d long-term
• Cognitive testing every 6 months
• Expected: 5–10% cognitive score improvement, increased cerebral blood flow

Stop/Reassess: If no cognitive improvement at 6 months. Consider switching NR NMN.

Safety

Interactions Table

Contraindications

Absolute:

• Active cancer undergoing chemotherapy or radiation (NAD+ supports cancer cell DNA repair via PARPs)
• Known allergy to nicotinic acid derivatives or specific formulation components

Relative:

• Pregnancy and lactation (no safety data; NAD+ levels increase naturally in pregnancy)
• Pediatric use (no safety data; NAD+ levels naturally high in youth)
• Severe liver disease — Child-Pugh C (impaired NAD+ metabolism; medical supervision required)
• Active bleeding disorders (theoretical mild antiplatelet effect)
• Active cancer in remission (discuss with oncologist — likely safe but uncertain)

Adverse Effects (ranked by frequency from clinical trials)

Common (1–10%):

• Mild nausea (5–10%) — transient, take with food
• Diarrhea (3–5%) — dose-dependent, usually resolves
• Stomach discomfort/bloating (3–5%) — start low, titrate up
• Headache (2–4%) — mild, transient
• Paradoxical fatigue (1–2%) — resolves after 1–2 weeks

Uncommon (0.1–1%):

• Insomnia/sleep disturbance (if taken late in day — shift to morning)
• Skin itching/rash (rare allergic reaction)
• Flushing (<1% with NR/NMN; >50% with niacin)

Rare (<0.1%):

• Liver enzyme elevation (extremely rare with NR/NMN; more common with high-dose niacin ER)
• Allergic reaction

Preclinical safety signals (not confirmed in humans):

• NR enhanced stress sensitivity in aged mice (PMID: 40665096) — cautionary, monitor
• Vitamin B3 derivatives may support pancreatic cancer cell survival in vitro (PMID: 41724424)
• NMN may be detrimental to sperm quality in mice — single study, unconfirmed

Safety profile summary: NAD+ precursors (NR, NMN) have excellent safety profiles in clinical trials up to 2000 mg/d (NR) and 1250 mg/d (NMN). Most adverse effects are mild and transient. No documented overdose toxicity. No tolerance development. No withdrawal symptoms. Can stop abruptly without tapering.

FAERS Signal Table (from BioMCP)

Reading FAERS data: NR had 32 total FAERS reports; only 1 identified NR as suspect drug (urticaria). NMN had 4 total reports; zero identified NMN as suspect. The vast majority are concomitant-drug reports where NR/NMN was co-administered but another drug was suspected. Per FAERS supplement noise principle: FAERS data for supplements is mostly noise from polypharmacy contexts, not oral supplementation signals.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

NAD+ precursors are NOT hepatotoxic. Concern relates to impaired metabolism in severe disease, not liver damage risk.

Cancer Patients

• Active treatment: Avoid NAD+ precursor supplementation during chemo/radiation (theoretical reduction in treatment efficacy via PARP-mediated DNA repair in tumor cells). New preclinical data (PMID: 41724424) shows B3 derivatives may support pancreatic cancer cell survival.
• Remission (no active treatment): Likely safe; no evidence of increased recurrence risk. Discuss with oncologist.
• Prevention (no cancer history): Likely safe. DNA repair benefits (prevents mutations) outweigh theoretical risks in healthy individuals. No human data showing increased cancer incidence from NAD+ precursors.

Synergies & Stacking

Note on TMG: Popular in biohacker stacks as a methyl donor alongside NMN. Theoretically sound (NMN → NAM → methylation via NNMT consumes SAM) but not clinically validated in humans. Low risk, low cost — reasonable precaution.

Individual Response Modifiers

Sex-Specific Considerations

Study population bias: Several key metabolic and sarcopenia RCTs enrolled predominantly or exclusively women. Male-specific response data is a significant gap.

Genetic Modifiers

Testing for NAMPT and SIRT1 variants is not routinely available. Practical approach: if NAM at adequate doses produces no benefit after 8 weeks, trial NR or NMN (bypasses NAMPT). If NR/NMN produces no benefit after 12 weeks, genetic variation may explain — consider dose escalation before abandoning.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-positive across ~3,000–6,000 unique reporters (Reddit r/Nootropics, r/Supplements, r/longevity, r/Biohackers, LongeCity, clinic review sites). Community is more analytically skeptical than typical supplement forums — many posters share bloodwork and track biomarkers.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No major pure NAD+/NMN MLM identified. General "wellness MLMs" bundle NAD+ precursors into multi-ingredient products.
• Influencer concentration: David Sinclair (28 company affiliations including MetroBiotech/NMN drug) is the dominant NMN promoter. Charles Brenner (ChromaDex chief science adviser) is the dominant NR promoter. Both have massive commercial conflicts of interest.
• Astroturfing signals: 14 of 22 Amazon NMN products contained no detectable NMN in independent testing (ProHealth/ChromaDex analysis). Formulaic 5-star Amazon reviews from low-karma accounts. SEO-optimized "best NMN" affiliate sites dominate search results.
• Commercial bias: The NR vs NMN debate is substantially a commercial rivalry (ChromaDex vs Chinese NMN manufacturers), not a settled scientific question. A 2026 head-to-head trial found both doubled circulating NAD+ with no significant difference.
• Product quality crisis: Quality control is the #1 community concern. Many "NMN" products are relabeled cheap nicotinamide. Third-party CoA verification is essential.

Folk vs Clinical Reality Check

Community-reported energy and cognition benefits align with clinical trial data showing improved mitochondrial function and cerebral blood flow. The ~25–30% "felt nothing" rate is consistent with expected non-responder populations in supplement trials (age, genetic variation, baseline NAD+ status). The insomnia reports align with NAD+'s role in circadian rhythm regulation. Where community diverges from clinical data: gray hair reversal claims lack RCT support; the "Sinclair Stack" as a combined protocol has never been studied in humans; community doses frequently exceed studied ranges; IV NAD+ clinic claims far exceed evidence (blood NAD+ ≠ intracellular NAD+). The NMN product quality crisis means many community "non-responders" may never have taken actual NMN.

Deep Dive: Mechanisms & Research

Key Mechanisms (with clinical translation status)

NAD+ serves three critical signaling roles beyond its classical redox function:

1. Sirtuin activation (SIRT1-7): NAD+-dependent deacetylases regulate gene expression, mitochondrial biogenesis (via SIRT1-PGC-1α axis), DNA repair, circadian rhythm, and inflammatory responses. Clinical translation: YES — NR/NMN activate this pathway in human trials (PMID: 31412242, 35235774).

2. PARP-dependent DNA repair (PARP1/2): NAD+ is consumed by PARPs during DNA damage detection and repair. Chronic PARP activation (from aging-related DNA damage) depletes NAD+ pools. Clinical translation: PARTIAL — DNA repair markers improve with NR (PMID: 27133167) but also raises the cancer concern (PARPs repair tumor cell DNA too).

3. CD38/CD157 ectoenzymes: Major NAD+ consumers that increase with aging. CD38 is responsible for most age-related NAD+ decline. Quercetin and apigenin inhibit CD38. Clinical translation: YES — CD38 inhibition is a validated strategy to preserve NAD+ (PMID: 33257636).

NAD+ compartmentalization: Cytoplasm, mitochondria, and nucleus maintain distinct NAD+ pools with independent regulation. Not all precursors boost all compartments equally — an active research area.

Novel precursors emerging: Nicotinic acid riboside (NAR) identified as a new NAD+ precursor pathway (Cell Metab 2025, PMID: 40315855). LNAD+ (novel oral form) showed intracellular NAD+ boosting without raising circulating NAD+ (preprint 2026). These may offer more targeted tissue delivery.

Head-to-head comparison (2026): Three NAD+ boosters showed distinct impacts on circulating NAD and microbial metabolism in a landmark human comparative study (Nat Metab, PMID: 41540253), suggesting precursor choice may matter for specific outcomes beyond just NAD+ levels.

NAD+ Reference Ranges

NAD+/NADH ratio: Young 7–10:1 (optimal) → Middle age 5–7:1 → Elderly 3–5:1 (suboptimal). Lower ratios indicate metabolic dysfunction.

Endogenous Synthesis Pathways

1. De novo (kynurenine pathway): Tryptophan → NAMN → NAD+. Rate-limited by QPRT. Primary in liver/kidney. Less efficient with aging.
2. Preiss-Handler: Dietary nicotinic acid → NAMN → NAD+. Three enzymatic steps.
3. Salvage (primary): Recycles nicotinamide from NAD+ consumption. Rate-limited by NAMPT (declines with aging). Most active pathway in most tissues.

Age-related NAD+ decline is driven by: decreased NAMPT expression, increased CD38 activity, chronic PARP activation, mitochondrial dysfunction, and circadian disruption.

Clinical Trials (from ClinicalTrials.gov via BioMCP)

Total registered trials: ~136 (87 NR + 25 NMN + 24 NAD supplementation with overlap). ~50+ completed, ~35+ active/recruiting.

Regulatory Status

• NR (FDA): GRAS (GRN 000635, Aug 2016). NDI notification accepted (2015). ChromaDex's Niagen is the only NR with both NDI and GRAS status. Not an approved drug.
• NR (EFSA/EU): Authorized as Novel Food (2019). Safe up to 300 mg/d general population; 500 mg/d for FSMP. Commission Implementing Regulation EU 2022/1160.
• NMN (FDA): Turbulent history. NDI accepted (May 2022) → FDA invoked drug preclusion rule (Nov 2022, due to MetroBiotech's MIB-626 IND) → NPA lawsuit (Aug 2024) → FDA reversed in Sept–Oct 2025, declaring NMN lawful as a dietary supplement.
• NMN (EFSA/EU): No Novel Food authorization as of April 2026.
• NMN (Asia): Widely sold in Japan (no restriction) and China (functional food; China produces ~84% of global NMN supply).
• Regulatory context: NR's GRAS status reflects years of ChromaDex investment in regulatory science. NMN's regulatory saga was driven by MetroBiotech (David Sinclair co-founded) attempting to capture NMN as a drug, which would have eliminated supplement competition. The 2025 FDA reversal restored NMN's supplement status.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to mechanism: NAD+ biology is genuinely important, but "central coenzyme in 500+ reactions" ≠ "supplementation fixes everything." Many mechanistic pathways don't translate clinically.
• Hasty generalization: Extensive animal longevity data does not guarantee human longevity benefit. Most disease-specific protocols (autoimmune, IBD, Hashimoto's, celiac) in the previous version of this file were speculative extrapolations from general NAD+ biology, not supported by disease-specific human trials.
• Cherry-picking: Published NAD+ trials are generally positive (publication bias). Null results exist — Dollerup 2018 (PMID: 30019234) showed "modest" metabolic effects despite adequate dosing and design.
• Appeal to authority: David Sinclair's academic credentials are real but his 28 company affiliations create massive conflicts. Charles Brenner's science is solid but he is ChromaDex's chief science adviser. Independent replication from neither camp is the gold standard.
• Inflated PMID counts: "766+ PMIDs" in the previous file was misleading — this includes all NAD+ biochemistry literature, not supplementation trials. Actual supplementation-specific clinical trials number ~50+.

Evidence Gaps

• No head-to-head NR vs NMN long-term outcome trial (2026 comparison was 14 days only)
• No human longevity data (requires decades; only biomarker surrogates available)
• No completed Alzheimer's-specific RCT showing clinical benefit (trials ongoing)
• Pediatric safety completely unknown
• Pregnancy/lactation safety not studied
• Long-term safety (>2 years continuous) data limited
• Sex-specific response poorly characterized (most RCTs enrolled primarily one sex)
• Optimal dose for specific diseases not established (extrapolated from general population)
• Genetic factors (NAMPT, SIRT variants) affecting response poorly understood
• Cancer interaction data limited to preclinical — no human cancer incidence data from NAD+ supplementation
• NOPARK Phase 3 results (N=410, Parkinson's) not yet published — could significantly shift the evidence landscape

Bias Flags (Mode 4: First Principles)

• NAD+ decline with aging is well-established across multiple independent research groups — this is not hype.
• Precursor supplementation demonstrably raises NAD+ levels — replicated finding.
• The key uncertainty is whether raising NAD+ levels produces clinically meaningful outcomes beyond biomarker changes. For metabolic health and BP: probably yes. For longevity: unknown.
• Most "condition-specific protocols" (autoimmune, GI, rare diseases) are mechanistic extrapolations dressed as clinical guidance. Honest approach: present the mechanism, note the absence of disease-specific RCTs, and distinguish "biologically plausible" from "clinically proven."
• The 5/5 ratings in the previous file were generous. Most NAD+ studies are small (N<100) and short-duration (≤12 weeks). The new meta-analyses add weight but individual study quality varies.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Reverse aging," "cellular energy," "fountain of youth" claims in supplement marketing exceed evidence. "Clinical strength NAD+" on oral NAD+ products is misleading (oral NAD+ doesn't work).
• Influencer economics: David Sinclair (MetroBiotech, InsideTracker, 28 companies) is the dominant NMN promoter. His company's letter to FDA preceded the 2022 NMN supplement ban attempt — widely perceived as trying to capture NMN as a proprietary drug. Charles Brenner (ChromaDex) actively attacks NMN on social media. Bryan Johnson ("Blueprint") drives NMN sales through massive media presence with his own supplement brand. Andrew Huberman, Dave Asprey, Ben Greenfield, Mark Hyman all promote NAD+ boosters with varying disclosure.
• Counter-narrative manipulation: No competing pharma product for NAD+ boosting → low incentive for pharma fearmongering. Counter-narratives are mostly from within the NAD+ space itself (NR advocates attacking NMN and vice versa).
• Cui bono summary: NR manufacturers (ChromaDex/Tru Niagen) profit from NR; Chinese NMN manufacturers (84% global supply) and Sinclair-adjacent companies profit from NMN; IV NAD+ clinics ($200–500/session) profit from dramatic delivery; biohacker influencers profit from content and affiliate links. Nobody profits from nicotinamide (too cheap to brand). Independent science comes from groups with no product stake.
• Red team highlight: The single most concerning angle: the NR vs NMN debate is almost entirely a commercial rivalry, not a scientific one. The 2026 head-to-head trial showed no significant difference, yet the debate persists because companies need product differentiation. Consumers absorb the controversy as if it's scientific, when it's largely marketing.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 6/10 — addresses fundamental cellular energy and repair pathways with strong mechanistic rationale; strongest clinical case in adults >40 with metabolic risk factors, early Parkinson's, or mitochondrial dysfunction. Human outcome data beyond biomarkers remains limited, capping general-population utility.
• Opportunity cost: $60–150/month for NR/NMN vs $5–10/month for NAM. Financial cost is the main barrier. Complexity cost is low (one pill/day). Adding NAD+ precursors doesn't preclude other interventions.
• Verdict: CONDITIONAL
• Conditions: Strongest case for: (1) adults >40 with metabolic risk factors (pre-diabetes, elevated BP, metabolic syndrome), (2) early Parkinson's disease (NADPARK data), (3) individuals with documented mitochondrial dysfunction or significant fatigue. Weaker case for: healthy young adults, "general longevity" without specific risk factors, athletes (limited performance data). If budget-constrained: NAM 250–500 mg/d is a reasonable starting point at 1/20th the cost.

Bottom Line

NAD+ precursors are among the better-evidenced longevity supplements, but the evidence base is still modest — mostly small, short RCTs. The strongest clinical signals are for metabolic health (multiple RCTs + meta-analyses), blood pressure (replicated), and Parkinson's disease (landmark NADPARK trial, Phase 3 pending). Safety is excellent. The NR vs NMN debate is primarily commercial. Product quality is the #1 practical risk — many NMN products contain no active ingredient. For most people over 40 with metabolic concerns: NR (GRAS, most data) or NMN (legal, growing data) at 500–1000 mg/d is a reasonable, well-tolerated intervention with modest expected benefit. For healthy young adults: probably unnecessary. For active cancer patients: avoid.

Practical Notes

Brands & Product Selection

Quality markers (essential): Third-party testing (USP, NSF, ConsumerLab, Informed Choice for athletes). ≥98% purity for NR/NMN. CoA (Certificate of Analysis) available on manufacturer website. Batch/lot numbers and expiration dates on label.

Red flags: "Proprietary blend" hiding doses. "Instant NAD+ boost" claims. No third-party testing. "NAD+ oral tablets" claiming high bioavailability. Price <$30/month for 500 mg+ daily (likely not real NMN). Suspiciously uniform 5-star Amazon reviews.

NR brands with documented testing: Tru Niagen (ChromaDex; NSF Certified, original NR research partner), Thorne ResveraCel, Life Extension NAD+ Cell Regenerator, Elysium Basis (NR + pterostilbene). NMN brands with documented testing: ProHealth Longevity (99%+ purity), Alive By Science, DoNotAge, Renue by Science. NAM: NOW Foods Niacinamide (USP), Thorne Niacinamide (NSF), Pure Encapsulations.

Storage & Handling

Room temperature (15–25°C); protect from direct sunlight (UV degradation); keep dry. Refrigeration may extend shelf life slightly. Unopened: 2–3 years. Opened: 12–18 months if stored properly. NR/NMN powder stable in water for several hours — consume within 4 hours if mixed.

Palatability & Compliance

NR/NMN capsules: swallow whole (most common). NMN powder: slightly bitter; mixes in water or smoothies. Sublingual NMN: hold under tongue 30–60 seconds (absorption benefit not proven over oral). Niacin: always with food (reduces flushing); extended-release preferred.

Exercise & Circadian Timing

Morning dosing (7–9 AM) aligns with circadian NAD+ synthesis peak (NAMPT is circadian-regulated). Pre-workout (30–60 min): may enhance mitochondrial function during exercise. Avoid evening dosing if insomnia occurs. Split dosing (AM/PM) may maintain more stable NAD+ levels for doses >750 mg/d.

Reference Ranges (Expected Biomarker Changes)

Note: Blood NAD+ is a poor indicator of tissue/intracellular NAD+. Clinical response and functional biomarkers (BP, glucose, strength) are better outcome measures than NAD+ blood tests.

Cost

Generic brands with third-party testing offer 30–50% savings vs premium brands with equivalent quality. Buy 3–6 month supply for bulk discounts.

What We Don't Know

• Whether raising NAD+ levels translates to human longevity (requires decades of data)
• Whether NR or NMN is truly superior for any specific indication (2026 head-to-head was only 14 days)
• Long-term safety beyond 2 years of continuous use
• Optimal dose for specific diseases (most doses extrapolated from general population)
• How genetic variation (NAMPT, SIRT1/3, CD38 polymorphisms) affects individual response
• Whether NAD+ precursors modify cancer risk in either direction in humans
• Safety in pregnancy, lactation, and pediatric populations
• Whether tissue-targeted delivery (nanoparticles, novel precursors like NAR) will outperform current options
• Whether CD38 inhibition (quercetin, apigenin) combined with precursors produces meaningfully better outcomes
• The NOPARK Phase 3 results (N=410, Parkinson's) — could significantly change the evidence landscape
• Whether NMN's theoretical sperm quality concern (one mouse study) is relevant in humans
• Whether IV NAD+ offers any benefit over oral precursors for intracellular NAD+ (likely not)

References

Meta-Analyses & Systematic Reviews (2024–2026)

• PMID: 41901064 — NMN and blood pressure: SR + MA of RCTs (2026)
• PMID: 39116016 — NMN on glucose/lipid metabolism: SR + MA of RCTs (2025)
• PMID: 39531138 — NMN on glucose/lipid metabolism: independent MA of RCTs (2024)
• PMID: 39111741 — NAD+ precursors on metabolic syndrome parameters: SR + MA (2024)
• PMID: 40275690 — NMN/NR on skeletal muscle mass and function: SR + MA (2025)
• PMID: 39185644 — NMN on muscle/liver functions in elderly: SR + MA (2025)
• PMID: 41655607 — NAD+ supplementation for anti-aging: PRISMA SR (2026)
• PMID: 41160202 — NMN for oocyte quality: SR + transcriptomics (2026)
• PMID: 37971292 — NR and NMN critical review of biological effects (2024)

Landmark Human RCTs

• PMID: 33888596 — Yoshino 2021, Science: NMN 250 mg/d improved insulin sensitivity in prediabetic women (N=25, RCT)
• PMID: 29599478 — Martens 2018, Nat Commun: Chronic NR supplementation well-tolerated, elevates NAD+, reduces BP and arterial stiffness (N=24, crossover RCT)
• PMID: 31412242 — Elhassan 2019, Cell Rep: NR 1000 mg/d increased muscle NAD+ metabolome, anti-inflammatory signatures in aged men (N=12, crossover RCT)
• PMID: 35235774 — Brakedal 2022, Cell Metab: NADPARK — NR 1000 mg/d in Parkinson's (N=30, RCT)
• PMID: 32060194 — Remie 2020, Am J Clin Nutr: NR 2000 mg/d improved mito function, reduced liver fat (N=13, crossover RCT)
• PMID: 35215405 — Kim 2022, GeroScience: NMN 250 mg/d improved muscle strength in elderly women (N=66, RCT)
• PMID: 36482258 — Yi 2023, GeroScience: NMN 300 mg/d multicenter dose-dependent safety/efficacy (N=80, RCT)
• PMID: 30019234 — Dollerup 2018, Am J Clin Nutr: NR 2000 mg/d in obese men — safe, modest effects (N=40, RCT)
• PMID: 32078450 — Irie 2020, Endocr J: NMN 250 mg/d increased NAD+ metabolites in Japanese men (N=10, RCT)
• PMID: 31278280 — Conze 2019, Sci Rep: NR up to 2000 mg/d long-term safety (N=140, RCT)

2024–2026 Human Trials

• PMID: 38871717 — NICE trial: NR for PAD, Phase 3 (N=90, Nat Commun 2024)
• PMID: 39548320 — NR for COPD airway inflammation (Nat Aging 2024)
• PMID: 40459998 — NR for Werner syndrome, Japan crossover RCT (Aging Cell 2025)
• PMID: 40770531 — NR + exercise for hypertension, pilot (GeroScience 2025)
• PMID: 40954388 — NAD+ for ischemic heart failure, RCT (Am J Cardiovasc Drugs 2026)
• PMID: 41705654 — NMN anti-inflammatory effects after BFR exercise, Taiwan (J Int Soc Sports Nutr 2026)
• PMID: 41540253 — Head-to-head comparison of three NAD+ boosters (Nat Metab 2026)
• PMID: 38191197 — Long-term NMN in healthy Japanese men — safety, metabolism, sleep (Endocr J 2024)
• PMID: 37994989 — NR for MCI in older adults (GeroScience 2024)
• PMID: 37899683 — Long-term NR in ataxia telangiectasia (Mov Disord 2024)
• PMID: 40069789 — Oral nicotinamide PK/PD in early Alzheimer's (NEAT trial, Alzheimers Res Ther 2025)
• PMID: 38016950 — NR-SAFE: high-dose NR safety in Parkinson's (Nat Commun 2023)
• PMID: 41502156 — NR for small nerve fiber degeneration (J Peripher Nerv Syst 2026)

Mechanistic & Preclinical

• PMID: 27127236 — Zhang 2016, Science: NMN reverses age-related mito dysfunction in mice
• PMID: 22682724 — Cantó 2012, Cell Metab: NR enhances oxidative metabolism via SIRT1-PGC-1α
• PMID: 28899755 — Fang 2017, Trends Mol Med: NAD+ in aging — mechanisms and translation
• PMID: 27133167 — Fang 2016, Cell: NMN restored DNA repair capacity in aged cells
• PMID: 40315855 — NAR as novel NAD+ precursor pathway (Cell Metab 2025)
• PMID: 41724424 — B3 derivatives support pancreatic cancer cell survival (Cancer Lett 2026) — SAFETY
• PMID: 40665096 — NR enhances stress sensitivity in aged mice (GeroScience 2026) — SAFETY
• PMID: 41121420 — Sex-specific NR + B vitamin benefits in heart failure (Biol Sex Differ 2025)
• PMID: 41870519 — Topical NAD+ skinbooster for melasma, Korea (Aesthetic Plast Surg 2026)
• PMID: 41665963 — Epidermal NAD+ deficiency induces skin inflammation (JCI Insight 2026)
• PMID: 41709697 — NAD ameliorates Alzheimer's pathology via REST (Brain 2026)

Disease-Specific

• PMID: 29686375 — Poyan Mehr 2018, Nat Med: NAD+ repletion protects kidneys
• PMID: 36515353 — Vreones 2022, Aging Cell: Oral NR raises NAD+ and lowers neurodegenerative biomarkers in neuronal plasma vesicles
• PMID: 37994989 — Orr 2024, GeroScience: NR improves cognitive function in MCI
• PMID: 33964073 — Liao 2021, J Int Soc Sports Nutr: NMN improves aerobic capacity in runners
• PMID: 25456740 — Brown 2014, Cell Metab: SIRT3 prevents noise-induced hearing loss
• PMID: 20602996 — Someya 2010, Cell: NAD+ depletion in age-related hearing loss
• PMID: 33454734 — Abdellatif 2021, Circulation: NAD+ in cardiovascular aging
• PMID: 30766476 — Santos 2019, J Gerontol: NR effects on physical function in aging

Reviews & Guidelines

• PMID: 26785480 — Verdin 2015, Science: NAD+ in aging, metabolism, neurodegeneration
• PMID: 33257636 — Katsyuba 2020, Nat Metab: NAD+ homeostasis in health and disease
• PMID: 33947761 — Zapata-Pérez 2021, EMBO Mol Med: NAD+ homeostasis clinical implications
• PMID: 30098997 — Yaku 2018, Ageing Res Rev: NAD metabolism in aging and longevity
• PMID: 28721272 — Imai & Guarente 2016: NAD+ and sirtuins in aging/longevity control
• PMID: 40926126 — Targeting NAD+ in the clinic: challenges (Nat Aging 2025)

Pharmacogenomics

• PMID: 41257989 — NAD+/SIRT1 genetic risk and depression (Transl Psychiatry 2025)
• PMID: 41751605 — SIRT1 rs7069102 and diabetic retinopathy (Genes 2026)
• PMID: 39980831 — SIRT1 rs3758391 and T2DM susceptibility (Health Sci Rep 2025)

Additional Resources

• Examine.com: https://examine.com/supplements/nicotinamide-riboside/
• NIH ODS Niacin Fact Sheet: https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
• ClinicalTrials.gov: search "nicotinamide riboside" or "NMN" (~136 registered trials)
• ChromaDex Research Hub: https://www.chromadex.com/science/publications/